| Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia T Pabst, BU Mueller, P Zhang, HS Radomska, S Narravula, S Schnittger, ... Nature genetics 27 (3), 263-270, 2001 | 1161 | 2001 |
| High-dose daunorubicin in older patients with acute myeloid leukemia B Löwenberg, GJ Ossenkoppele, W van Putten, HC Schouten, C Graux, ... New England Journal of Medicine 361 (13), 1235-1248, 2009 | 997 | 2009 |
| Molecular minimal residual disease in acute myeloid leukemia M Jongen-Lavrencic, T Grob, D Hanekamp, FG Kavelaars, A Al Hinai, ... New England Journal of Medicine 378 (13), 1189-1199, 2018 | 841 | 2018 |
| AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t (8; 21) myeloid leukemia T Pabst, BU Mueller, N Harakawa, C Schoch, T Haferlach, G Behre, ... Nature medicine 7 (4), 444-451, 2001 | 609 | 2001 |
| High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study M Terwijn, WLJ van Putten, A Kelder, VHJ van der Velden, RA Brooimans, ... Journal of clinical oncology 31 (31), 3889-3897, 2013 | 559 | 2013 |
| Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group … HT Eich, V Diehl, H Görgen, T Pabst, J Markova, J Debus, A Ho, B Dörken, ... Journal of Clinical Oncology 28 (27), 4199-4206, 2010 | 539 | 2010 |
| Cytarabine dose for acute myeloid leukemia B Löwenberg, T Pabst, E Vellenga, W van Putten, HC Schouten, C Graux, ... New England Journal of Medicine 364 (11), 1027-1036, 2011 | 528 | 2011 |
| Molecular and translational classifications of DAMPs in immunogenic cell death AD Garg, L Galluzzi, L Apetoh, T Baert, RB Birge, JM Bravo-San Pedro, ... Frontiers in immunology 6, 588, 2015 | 420 | 2015 |
| PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin … P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ... The Lancet 390 (10114), 2790-2802, 2017 | 404 | 2017 |
| Risk assessment in patients with acute myeloid leukemia and a normal karyotype M Bienz, M Ludwig, BU Mueller, E Oppliger Leibundgut, D Ratschiller, ... Clinical Cancer Research 11 (4), 1416-1424, 2005 | 355 | 2005 |
| Heterozygous PU. 1 mutations are associated with acute myeloid leukemia BU Mueller, T Pabst, M Osato, N Asou, LM Johansen, MD Minden, ... Blood, The Journal of the American Society of Hematology 100 (3), 998-1007, 2002 | 338 | 2002 |
| Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells P Kirstetter, MB Schuster, O Bereshchenko, S Moore, H Dvinge, E Kurz, ... Cancer cell 13 (4), 299-310, 2008 | 319 | 2008 |
| Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling AD Patterson, O Maurhofer, D Beyoğlu, C Lanz, KW Krausz, T Pabst, ... Cancer research 71 (21), 6590-6600, 2011 | 304 | 2011 |
| Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia S Lugthart, S Gröschel, HB Beverloo, S Kayser, PJM Valk, ... Journal of clinical oncology 28 (24), 3890-3898, 2010 | 295 | 2010 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 290 | 2018 |
| ATRA resolves the differentiation block in t (15; 17) acute myeloid leukemia by restoring PU. 1 expression BU Mueller, T Pabst, J Fos, V Petkovic, MF Fey, N Asou, U Buergi, ... Blood 107 (8), 3330-3338, 2006 | 256 | 2006 |
| Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious … D Averbuch, G Tridello, J Hoek, M Mikulska, H Akan, ... Clinical Infectious Diseases 65 (11), 1819-1828, 2017 | 254 | 2017 |
| Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia M Terwijn, W Zeijlemaker, A Kelder, AP Rutten, AN Snel, WJ Scholten, ... PloS one 9 (9), e107587, 2014 | 254 | 2014 |
| Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results L Ades, MA Sanz, S Chevret, P Montesinos, P Chevallier, E Raffoux, ... Blood, The Journal of the American Society of Hematology 111 (3), 1078-1084, 2008 | 231 | 2008 |
| Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis T Pabst, M Eyholzer, J Fos, BU Mueller British journal of cancer 100 (8), 1343-1346, 2009 | 229 | 2009 |
